Literature DB >> 31852803

Organic Cation Transporters in Health and Disease.

Hermann Koepsell1.   

Abstract

The organic cation transporters (OCTs) OCT1, OCT2, OCT3, novel OCT (OCTN)1, OCTN2, multidrug and toxin exclusion (MATE)1, and MATE kidney-specific 2 are polyspecific transporters exhibiting broadly overlapping substrate selectivities. They transport organic cations, zwitterions, and some uncharged compounds and operate as facilitated diffusion systems and/or antiporters. OCTs are critically involved in intestinal absorption, hepatic uptake, and renal excretion of hydrophilic drugs. They modulate the distribution of endogenous compounds such as thiamine, L-carnitine, and neurotransmitters. Sites of expression and functions of OCTs have important impact on energy metabolism, pharmacokinetics, and toxicity of drugs, and on drug-drug interactions. In this work, an overview about the human OCTs is presented. Functional properties of human OCTs, including identified substrates and inhibitors of the individual transporters, are described. Sites of expression are compiled, and data on regulation of OCTs are presented. In addition, genetic variations of OCTs are listed, and data on their impact on transport, drug treatment, and diseases are reported. Moreover, recent data are summarized that indicate complex drug-drug interaction at OCTs, such as allosteric high-affinity inhibition of transport and substrate dependence of inhibitor efficacies. A hypothesis about the molecular mechanism of polyspecific substrate recognition by OCTs is presented that is based on functional studies and mutagenesis experiments in OCT1 and OCT2. This hypothesis provides a framework to imagine how observed complex drug-drug interactions at OCTs arise. Finally, preclinical in vitro tests that are performed by pharmaceutical companies to identify interaction of novel drugs with OCTs are discussed. Optimized experimental procedures are proposed that allow a gapless detection of inhibitory and transported drugs.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31852803     DOI: 10.1124/pr.118.015578

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  64 in total

1.  Serotonin homeostasis in the materno-foetal interface at term: Role of transporters (SERT/SLC6A4 and OCT3/SLC22A3) and monoamine oxidase A (MAO-A) in uptake and degradation of serotonin by human and rat term placenta.

Authors:  Rona Karahoda; Hana Horackova; Petr Kastner; Andreas Matthios; Lukas Cerveny; Radim Kucera; Marian Kacerovsky; Jurjen Duintjer Tebbens; Alexandre Bonnin; Cilia Abad; Frantisek Staud
Journal:  Acta Physiol (Oxf)       Date:  2020-05-18       Impact factor: 6.311

2.  Comparison of Hepatic Transporter Tissue Expression in Rodents and Interspecies Hepatic OCT1 Activity.

Authors:  Bridget L Morse; John K Fallon; Anil Kolur; Andrew T Hogan; Philip C Smith; Kathleen M Hillgren
Journal:  AAPS J       Date:  2021-04-26       Impact factor: 4.009

3.  Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies.

Authors:  Sook Wah Yee; Dina Buitrago; Adrian Stecula; Huy X Ngo; Huan-Chieh Chien; Ling Zou; Megan L Koleske; Kathleen M Giacomini
Journal:  FASEB J       Date:  2020-10-30       Impact factor: 5.191

4.  Cholinergic leukocytes in sepsis and at the neuroimmune junction in the spleen.

Authors:  Donald B Hoover; Megan D Poston; Stacy Brown; Sarah E Lawson; Cherie E Bond; Anthony M Downs; David L Williams; Tammy R Ozment
Journal:  Int Immunopharmacol       Date:  2020-03-03       Impact factor: 4.932

Review 5.  Role of SLC transporters in toxicity induced by anticancer drugs.

Authors:  Kevin M Huang; Muhammad Erfan Uddin; Duncan DiGiacomo; Maryam B Lustberg; Shuiying Hu; Alex Sparreboom
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-04-26       Impact factor: 4.481

Review 6.  The Interaction of Organic Cation Transporters 1-3 and PMAT with Psychoactive Substances.

Authors:  Julian Maier; Marco Niello; Deborah Rudin; Lynette C Daws; Harald H Sitte
Journal:  Handb Exp Pharmacol       Date:  2021

Review 7.  Functional and Biochemical Consequences of Disease Variants in Neurotransmitter Transporters: A Special Emphasis on Folding and Trafficking Deficits.

Authors:  Shreyas Bhat; Ali El-Kasaby; Michael Freissmuth; Sonja Sucic
Journal:  Pharmacol Ther       Date:  2020-12-10       Impact factor: 12.310

8.  Targeting OCT3 attenuates doxorubicin-induced cardiac injury.

Authors:  Kevin M Huang; Megan Zavorka Thomas; Tarek Magdy; Eric D Eisenmann; Muhammad Erfan Uddin; Duncan F DiGiacomo; Alexander Pan; Markus Keiser; Marcus Otter; Sherry H Xia; Yang Li; Yan Jin; Qiang Fu; Alice A Gibson; Ingrid M Bonilla; Cynthia A Carnes; Kara N Corps; Vincenzo Coppola; Sakima A Smith; Daniel Addison; Anne T Nies; Ralf Bundschuh; Taosheng Chen; Maryam B Lustberg; Joanne Wang; Stefan Oswald; Moray J Campbell; Pearlly S Yan; Sharyn D Baker; Shuiying Hu; Paul W Burridge; Alex Sparreboom
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-02       Impact factor: 11.205

Review 9.  Transport of Drugs and Endogenous Compounds Mediated by Human OCT1: Studies in Single- and Double-Transfected Cell Models.

Authors:  Bastian Haberkorn; Martin F Fromm; Jörg König
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

10.  Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients.

Authors:  Johannes Matthaei; Jürgen Brockmöller; Werner Steimer; Konstanze Pischa; Stefan Leucht; Maria Kullmann; Ole Jensen; Typhaine Ouethy; Mladen Vassilev Tzvetkov; Muhammad Rafehi
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.